Archive: February 24 2021
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Monoclonal Antibodies Prove to Be Novel Therapeutics for Myeloma
Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.
How do I manage the risk of infection in patients treated with immunotherapies?
During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Joshua Hill, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How do I manage the risk of infection in patients treated with immunotherapies?
Looking to Novel Immunotherapeutics in Relapsed/Refractory Multiple Myeloma
Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.